Gritstone bio, Inc. (GRTS)
| Market Cap | 251.87M |
| Revenue (ttm) | 18.34M |
| Net Income (ttm) | -116.67M |
| Shares Out | 73.01M |
| EPS (ttm) | -1.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,003,610 |
| Open | 3.48 |
| Previous Close | 3.43 |
| Day's Range | 3.38 - 3.62 |
| 52-Week Range | 1.71 - 14.42 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 11.56 (+235.1%) |
| Earnings Date | Aug 4, 2022 |
About GRTS
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small ... [Read more...]
Financial Performance
In 2021, Gritstone bio's revenue was $48.21 million, an increase of 1,094.30% compared to the previous year's $4.04 million. Losses were -$75.08 million, -28.71% less than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for GRTS stock is "Buy." The 12-month stock price forecast is 11.56, which is an increase of 235.07% from the latest price.
News
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced th...
Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022
Conference call to occur at 4:30pm ET on August 4 Conference call to occur at 4:30pm ET on August 4
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Pu...
-- Results, which were previously pre-printed in bioRxiv, show Gritstone's second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad neutralizing antibodies, T cell responses and off...
Gritstone Earns 2022 Great Place to Work Certification™
EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced th...
Best Penny Stocks to Buy in June? 3 to Watch Today
Check these 3 penny stocks out for your watchlist right now The post Best Penny Stocks to Buy in June? 3 to Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....
Gritstone to Participate in H.C. Wainwright Global Investment Conference
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced tha...
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines agai...
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of -3.03% and 16.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
-- Translational immunology data and cassette design capabilities enabled development of an optimized, KRAS-specific version of “off-the-shelf” vaccine candidate now in Phase 2 (SLATE-KRAS) -- -- GRANIT...
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 16.28% and 2.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Investors Hoping for News at Cancer Meeting That Will Boost Share Prices
Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association ...
Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates
-- Four trials now initiated for CORAL, Gritstone's second-generation COVID-19 program focused on delivering T cell enhanced self-amplifying mRNA (samRNA) vaccines -- -- Oncology programs advancing as p...
Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at...
-- Oral presentation to discuss how translational immunology data enabled iterative development of an optimized, KRAS-specific version of “off-the shelf” vaccine candidate; the optimized version is now ...
Gritstone to Participate in Cowen 42nd Annual Health Care Conference
EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunothe...
2 Beaten-Down Biotech Stocks That Could Make You Filthy Rich
These unloved biotechs have enormous upside potential.
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE f...
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA) reduc...
Gritstone Bio's COVID-19 Booster Dose Shows Early Neutralizing Antibody Responses
Gritstone bio Inc (NASDAQ: GRTS) has shared data from the first cohort (10 µg dose) of the Phase 1 booster trial of self-amplifying mRNA (samRNA) COVID-19 vaccine. The data demonstrated strong neutraliz...
Gritstone Announces Presentations during Three Upcoming Investor Conferences
EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunothe...
Gritstone Announces Changes to Its Board of Directors
-- Clare Fisher, accomplished corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1, 2022 --...
3 Under-the-Radar Biotech Stocks to Buy in 2022
They may deliver major gains down the road.
Gritstone bio, CEPI Expand COVID-19 Vaccine Agreement to Combat Omicron Variant
Gritstone bio Inc (NASDAQ: GRTS) and Coalition for Epidemic Preparedness Innovations (CEPI) have expanded their agreement to support the development of a self-amplifying mRNA (SAM) vaccine designed to t...
Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant
EMERYVILLE, Calif. and OSLO, Norway, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease...
Implied Volatility Surging for Gritstone (GRTS) Stock Options
Investors need to pay close attention to Gritstone (GRTS) stock based on the movements in the options market lately.
Gritstone Says Omicron Mutations Minimally Impact T-Cell Epitope Sequences In Its COVID-19 Vaccines
Gritstone bio Inc (NASDAQ: GRTS) announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying mRNA (SAM) COVID-19 vaccines are minimally impacted by the Omicron (B.1.1.52...